Who founded Pharmatrophix?

Pharmatrophix was founded by Frank M. Longo.

Who are Pharmatrophix's investors?

Pharmatrophix's investors include Dolby Family Ventures.

How much funding has Pharmatrophix raised?

Pharmatrophix has disclosed $10.3M raised across 1 round.

Where is Pharmatrophix headquartered?

Pharmatrophix is headquartered in Raleigh, US.

Pharmatrophix

Raleigh, US · Delaware corporation · 1 known investors

Find your way into Pharmatrophix

Paths you didn't know you had: your email and LinkedIn already hold routes to the Pharmatrophix team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Pharmatrophix is developing a small-molecule drug for Alzheimer's disease that acts upstream of amyloid, with Phase 2a trial imaging showing dose-dependent preservation of whole-brain connectivity. The company works in neurodegenerative disease drug development.

Biotech Healthtech

Founders & leadership

Frank M. Longo Co-FounderFrank M. Longo is a neurologist and neuroscientist with an MD and PhD in Neuroscience from the University of California, San Diego, and completed neurology residency and neurobiology fellowship at UCSF. He held leadership roles including Chair of Neurology at the University of North Carolina–Chapel Hill and Chair of the Department of Neurology and Neurological Sciences at Stanford Medicine until 2023, where his research has focused on neurodegenerative disease prevention and therapeutics.

Anne C. LongoSenior Advisor

Board

Robert SimsBoard director

Investors · 1

Dolby Family Ventureslisted by Dolby Family VenturesSan Francisco

How we know: Dolby Family Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$10.3M disclosed across 1 round · 2014

▶$10.3MraisedNov 2015 · 15 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Anne C. LongoExecutive Officer
Robert SimsDirector
Frank M. LongoDirector

Offering amount: $10.3M
Amount sold: $10.3M
First sale: Jun 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

ADvantage TherapeuticsADvantage Therapeutics is a biopharmaceutical company engaged in therapeutic drug development and clinical research, including NIH/PHS-funded studies evaluating the safety and effectiveness of drugs and treatments.

Companies working in the same space as Pharmatrophix.

Frequently asked questions

What does Pharmatrophix do?: Pharmatrophix is developing a small-molecule drug for Alzheimer's disease that acts upstream of amyloid, with Phase 2a trial imaging showing dose-dependent preservation of whole-brain connectivity. The company works in neurodegenerative disease drug development.
Who founded Pharmatrophix?: Pharmatrophix was founded by Frank M. Longo.
Who are Pharmatrophix's investors?: Pharmatrophix's investors include Dolby Family Ventures.
How much funding has Pharmatrophix raised?: Pharmatrophix has disclosed $10.3M raised across 1 round.
Where is Pharmatrophix headquartered?: Pharmatrophix is headquartered in Raleigh, US.